Kane Biotech to Participate in a Multinational Corporate Collaboration Project
03. Oktober 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to...
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
11. Juli 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with...
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
27. Juni 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
15. Mai 2024 08:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces its intent to commercialize the patented assay...
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
11. April 2024 09:45 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has reached an agreement in principle for...
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
20. März 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on...
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
19. März 2024 16:10 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 19, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
08. März 2024 09:00 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba...
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray
31. Januar 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™...
Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
25. Januar 2024 12:03 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its...